RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase by 40–80 mg/day at 1–2 week intervals based on blood pressure response |
|
Usual maintenance dose
|
40–80 mg once daily |
|
Maximum dose
|
320 mg once daily |
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase every 3–7 days based on clinical response and heart rate |
|
Usual maintenance dose
|
80–160 mg once daily |
|
Maximum dose
|
240 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
20 mg once daily |
|
Titration
|
Titrate to decrease resting heart rate by approximately 25% or to achieve heart rate of 55–60 bpm |
|
Usual maintenance dose
|
40–80 mg once daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Long-term for primary/secondary prophylaxis |
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase by 40 mg every 2–4 weeks based on response and tolerability |
|
Usual maintenance dose
|
80–160 mg once daily |
|
Maximum dose
|
240 mg/day |
|
Duration
|
Minimum 2–3 months trial; continue 6–12 months if effective, then consider tapering |
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase every 3–7 days based on heart rate and symptom control |
|
Usual maintenance dose
|
40–160 mg once daily |
|
Maximum dose
|
160 mg/day (higher doses rarely needed) |
|
Duration
|
Until euthyroid state achieved with definitive therapy (antithyroid drugs, radioiodine, or surgery) |
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase gradually based on heart rate and clinical response |
|
Usual maintenance dose
|
40–160 mg once daily |
|
Maximum dose
|
160–240 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day once daily |
|
Titration
|
Increase every 3–7 days based on heart rate and QTc response |
|
Usual maintenance dose
|
1–2 mg/kg/day once daily |
|
Maximum dose
|
4 mg/kg/day |
|
Minimum age
|
Not recommended below 3 years except under paediatric electrophysiologist guidance |
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day once daily |
|
Titration
|
Increase by 0.5 mg/kg/day every 2–4 weeks based on response |
|
Usual maintenance dose
|
1–2 mg/kg/day once daily |
|
Maximum dose
|
2.5 mg/kg/day or 160 mg/day (whichever is lower) |
|
Duration
|
Minimum 2–3 months trial |
|
Minimum age
|
Not recommended below 6 years without paediatric neurology guidance |
| eGFR (mL/min/1.73m²) | Recommendation |
| >80 | No dose adjustment required |
| 50–80 | Reduce dose by 50% or extend dosing interval to every 48 hours |
| 10–50 | Use 25–50% of usual dose; monitor heart rate and blood pressure closely |
| <10 | Use with extreme caution; avoid if bradycardia risk is high |
| Severity | Recommendation |
| Mild impairment | No specific dose adjustment required |
| Moderate impairment | No specific dose adjustment required; monitor haemodynamic parameters |
| Severe impairment | Use with caution; consider reduced dosing frequency; monitor for excessive bradycardia or hypotension due to altered haemodynamics |
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed; nadolol crosses placenta |
| Risk | Fetal bradycardia, hypoglycaemia, intrauterine growth restriction, low birth weight |
| Preferred alternatives | Labetalol, methyldopa for hypertension in pregnancy (better established safety data); propranolol for other indications |
| When it may be used | Only if benefit clearly outweighs risk and preferred alternatives are not suitable |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose monitoring for 48–72 hours post-delivery |
| Consideration | Recommendation |
| Compatibility | Compatible with caution |
| Drug levels in milk | Low to moderate; long half-life may lead to accumulation in infant |
| Preferred alternatives | Propranolol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding, weight gain, signs of beta-blockade (lethargy, poor feeding) |
| Consideration | Recommendation |
| Starting dose | 20–40 mg once daily |
| Titration | Slower titration recommended (increase dose at 2-week intervals) |
| Risks | Bradycardia, hypotension, dizziness, falls, cognitive effects, depression |
| Monitoring | Renal function, heart rate, orthostatic blood pressure |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; increased risk of bradycardia, AV block, heart failure |
Avoid combination or use with extreme caution under specialist supervision
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped without first tapering beta-blocker |
Discontinue nadolol several days before stopping clonidine
|
| Amiodarone | Additive bradycardia and conduction abnormalities |
Use with caution; monitor ECG and heart rate closely
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Additive negative inotropic effects; risk of severe bradycardia and heart failure |
Avoid or use with extreme caution
|
| Insulin and sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor); may prolong hypoglycaemia |
Monitor blood glucose closely; educate patient on hypoglycaemia signs
|
| MAOIs | Risk of severe hypertension |
Avoid combination
|
| Fingolimod | Additive bradycardia risk |
Avoid initiation of fingolimod in patients on nadolol
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| NSAIDs | May blunt antihypertensive effect via prostaglandin inhibition and sodium retention | Monitor blood pressure |
| Digoxin | Additive bradycardia risk | Monitor heart rate; consider dose adjustment |
| Rifampicin | May reduce beta-blocker efficacy via hepatic enzyme induction | Monitor clinical response; may need dose adjustment |
| Tricyclic antidepressants | Additive bradycardia and orthostatic hypotension | Monitor heart rate and blood pressure |
| SSRIs (fluoxetine, paroxetine) | CYP2D6 inhibition may increase nadolol levels; potential additive bradycardia | Monitor heart rate |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist of beta-blocker use; do not discontinue abruptly before surgery |
| Antithyroid drugs | May require nadolol dose reduction as patient becomes euthyroid | Monitor heart rate and adjust dose |
| Ergot alkaloids | Additive vasoconstriction | Monitor for peripheral ischaemia |
| Antipsychotics | Additive hypotension | Monitor blood pressure |
| Adverse Effect | Clinical Note |
| Symptomatic bradycardia or AV block | May require dose reduction or discontinuation; atropine or temporary pacing may be needed in severe cases |
| Bronchospasm / Exacerbation of asthma or COPD | Discontinue immediately; non-selective beta-blockers contraindicated in reactive airway disease |
| Heart failure decompensation | Monitor closely in patients with borderline cardiac function; discontinue if new or worsening heart failure |
| Severe hypotension | Especially with concurrent antihypertensives or in volume-depleted patients |
| Masked hypoglycaemia | Particularly dangerous in insulin-dependent diabetics; educate patients |
| Withdrawal-induced angina or myocardial infarction | Always taper gradually over 1–2 weeks; never stop abruptly |
| Severe depression or psychosis | Rare; discontinue if significant psychiatric symptoms develop |
| Raynaud’s phenomenon / Peripheral ischaemia | May require discontinuation |
| Phase | Parameters |
|
Baseline
|
Heart rate, blood pressure, ECG, renal function (serum creatinine, eGFR), blood glucose (in diabetics), thyroid function (if indicated) |
|
After initiation/dose change
|
Heart rate and blood pressure after 1–2 weeks; symptoms of fatigue, dizziness, depression |
|
Long-term
|
Heart rate, blood pressure, renal function every 3–6 months in stable patients; periodic assessment of mood and exercise tolerance |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.